KEYNOTE-024: Extended Survival Outcomes With First-line Pembrolizumab in PD-L1+ NSCLC

June 2-6, 2017; Chicago, Illinois
Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 270 KB
Released: June 8, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Download these expert-selected slides covering current recommendations on evaluating and treating patients for NTRK fusion-positive cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Alexander Drilon, MD Theodore Laetsch, MD Released: June 16, 2021

EHR data analysis from ASCO 2021 showed that NGS testing and clinical trial participation were less likely among Black patients with NSCLC than White patients, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Download these expert-selected slides on testing for TRK fusions in your patients with cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Released: June 11, 2021

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue